Zobrazeno 1 - 10
of 54
pro vyhledávání: '"59"'
Autor:
Maliha Nusrat, Riham Katkhuda, James P. Allison, Jason Roszik, David G. Menter, Scott Kopetz, Michael J. Overman, Kanwal Pratap Singh Raghav, Van K. Morris, Dipen M. Maru, Padmanee Sharma, Jorge Blando
Publikováno v:
Journal of Clinical Oncology. 36:653-653
653 Background: PI3K pathway is a known modulator of anti-tumor immune response and is frequently activated in CRC through genetic alterations such as PTEN loss (PTENloss) and PIK3CA mutations (PIK3CAmut). This study aims to determine the impact of t
Autor:
Jose Carlos Martinez Avila, Jair Tenorio, Hoi Tong, Lorena Ostios, Nuria Rodriguez Salas, Alberto M. Borobia, María Teresa García Morales, Jesus Miranda, Mario Muñoz, Gema Gordo
Publikováno v:
Journal of Clinical Oncology. 36:718-718
718 Background: mCRC is the 2º cause of death in the world. Development of targeted therapies has increased the survival. The efficacy of these drugs (such Bevacizumab and monoclonal antibodies against EGFR) depends on the use of genetic biomarkers
Autor:
Pamela A. Shaw, Noelle V. Frey, Zhaohui Zheng, Carl H. June, David L. Porter, Simon F. Lacey, Laura S Motley, Farzana Nazimuddin, Susan R. Rheingold, Colleen Callahan, Christine Barker, Shannon L. Maude, J. Joseph Melenhorst, David M. Barrett, Richard Aplenc, Bruce L. Levine, David T. Teachey, Stephan A. Grupp
Publikováno v:
Journal of Clinical Oncology. 34:3011-3011
3011Background: Targeted immunotherapy with chimeric antigen receptor (CAR)-modified T cells can produce potent anti-tumor responses. We previously reported complete remissions (CR) and prolonged persistence in children and adults with relapsed/refra
Autor:
Teresa Curiel, J.M. Piulats, Salvador Martín-Algarra, Montserrat Gomà, Miriam Redrado, Luis Merino, Alfonso Berrocal-Jaime, Mar Varela, Rafael López Castro, Lorenzo Alonso Carrión, Alfonso Calvo González, Enrique Espinosa, Delvys Rodriguez-Abreu, Antonio Rullan
Publikováno v:
Journal of Clinical Oncology. 39:586-598
PURPOSE This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligi
Autor:
Keith T. Flaherty, Lyndsay Harris, April K.S. Salama, P. Mickey Williams, Carlos L. Arteaga, Alice P. Chen, Jong-In Park, Barbara A. Conley, Deborah K. Armstrong, Larry Rubinstein, Edith P. Mitchell, Robert Gray, James A. Zwiebel, Lisa M. McShane, Shuli Li, Helen X. Chen, Peter J. O'Dwyer, Erin Macrae, Stanley R. Hamilton, David Patton
Publikováno v:
Journal of Clinical Oncology. 38:3895-3904
PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the
Autor:
Jeffrey C. Goh, Jeri Kim, Haiyan Wu, Tuomo Alanko, Satoshi Fukasawa, Ahmet Sezer, Christian Heinrich Poehlein, Ranaan Berger, Se Hoon Park, Christopher J. Hoimes, Susan Feyerabend, Kristiina Ojamaa, Emmanuel S. Antonarakis, Chunde Li, Charles G. Drake, Ping Qiu, Giuseppe Procopio, Aurelius Omlin, Ronald de Wit, Marine Gross-Goupil, Johann S. de Bono, Josep M. Piulats, Ken-ichi Tabata, Ulka N. Vaishampayan
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Clinical Oncology, 38, 395-405. American Society of Clinical Oncology
Universidad de Barcelona
Journal of Clinical Oncology, 38, 395-405. American Society of Clinical Oncology
PURPOSE Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)–positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and safety of pembrolizumab in three
Autor:
Paolo A. Ascierto, Emiliano Calvo, Marina Tschaika, Dirk Jaeger, Padmanee Sharma, Katriina Peltola, Jeffry Evans, Yelena Y. Janjigian, Filippo de Braud, Christopher T. Harbison, Ian Chau, Johanna C. Bendell, Dung T. Le, Joseph Kim, Patrick A. Ott, Cecile Dorange
Publikováno v:
Journal of Clinical Oncology. 36:2836-2844
Purpose Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction canc
Autor:
Sarah T. Hawley, Ann S. Hamilton, Lauren P. Wallner, Allison W. Kurian, Monica Morrow, Kevin C. Ward, M. Chandler McLeod, Steven J. Katz, Reshma Jagsi
Publikováno v:
Journal of Clinical Oncology. 36:1218-1224
Purpose Little is known about the extent to which genetic counseling is integrated into community practices for patients newly diagnosed with breast cancer. We examined the receipt of clinically indicated genetic counseling in these patients. Patient
Autor:
Jessica J. Lin, Alice T. Shaw
Publikováno v:
Journal of Clinical Oncology. 34:3363-3365
Recent years have borne witness to the development of numerous anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for patients with ALK-rearranged non–small-cell lung cancer (NSCLC). Crizotinib, amultitargeted ALK/ROS1/MET inhibitor
Autor:
Zev A. Wainberg, Pankaj Bhargava, Dung Thai, Jean-Philippe Metges, Kai-Keen Shiu, Carrie Baker Brachmann, Daniel V.T. Catenacci, Lucjan Wyrwicz, David Cunningham, Manish A. Shah
Publikováno v:
Journal of Clinical Oncology. 37:75-75
75 Background: Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9). Preclinical studies suggest that MMP9 inhibition relieves immune suppression and promotes T-cell infiltration to potentiate checkpoint blocka